TipRanks
Advertisement
Advertisement

DE:2US0 Stock Latest News

NextCure Faces Court Review of Reverse Stock Split
Company AnnouncementsNextCure Faces Court Review of Reverse Stock Split
8d ago
8K
NXTC
NextCure Ends Beltsville Lease to Cut Operating Costs
PremiumCompany Announcements
NextCure Ends Beltsville Lease to Cut Operating Costs
30d ago
8K
NXTC
NextCure reports Q2 EPS ($2.80), consensus ($1.92)
PremiumThe Fly
NextCure reports Q2 EPS ($2.80), consensus ($1.92)
2M ago
NXTC
NextCure trading resumes
PremiumThe Fly
NextCure trading resumes
3M ago
NXTC
NextCure trading halted, volatility trading pause
PremiumThe Fly
NextCure trading halted, volatility trading pause
3M ago
NXTC
Analyst Initiates Buy on NextCure as Merger with Avere Positions AVR-001 for Well-Financed Late-Stage Development in Psoriasis and UC
PremiumRatingsAnalyst Initiates Buy on NextCure as Merger with Avere Positions AVR-001 for Well-Financed Late-Stage Development in Psoriasis and UC
3M ago
NXTC
NextCure Announces Transformative All-Stock Merger With Avere
Premium
Company Announcements
NextCure Announces Transformative All-Stock Merger With Avere
3M ago
8K
NXTC
Midday Fly By: IBM warns on Q2 outlook, Goldman reports sharp beat
Premium
The Fly
Midday Fly By: IBM warns on Q2 outlook, Goldman reports sharp beat
3M ago
GS
PM
Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That
PremiumTipRanks Newswire
Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That
3M ago
LLY
NXTC
NextCure, Avere Therapeutics enter definitive merger agreement
PremiumThe Fly
NextCure, Avere Therapeutics enter definitive merger agreement
3M ago
NXTC
NextCure, Avere Therapeutics enter definitive merger agreement
PremiumThe Fly
NextCure, Avere Therapeutics enter definitive merger agreement
3M ago
NXTC
NextCure Shareholders Approve Expanded Omnibus Incentive Plan
PremiumCompany Announcements
NextCure Shareholders Approve Expanded Omnibus Incentive Plan
3M ago
8K
NXTC
NextCure share weakness overdone, says Lucid Capital
PremiumThe FlyNextCure share weakness overdone, says Lucid Capital
4M ago
NXTC
NextCure presents Phase 1 data for SIM0505 in gynecologic cancers
Premium
The Fly
NextCure presents Phase 1 data for SIM0505 in gynecologic cancers
4M ago
NXTC
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data
Premium
Company Announcements
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data
4M ago
8K
NXTC
NextCure initiated with a Buy at Lucid Capital
PremiumThe Fly
NextCure initiated with a Buy at Lucid Capital
5M ago
NXTC
NextCure reports Q1 EPS ($1.87), consensus ($2.03)
PremiumThe Fly
NextCure reports Q1 EPS ($1.87), consensus ($2.03)
5M ago
NXTC
NextCure initiates dose optimization portion of SIM0505 study
PremiumThe Fly
NextCure initiates dose optimization portion of SIM0505 study
5M ago
NXTC
NextCure granted Fast Track Designation for SIM0505 by FDA
PremiumThe Fly
NextCure granted Fast Track Designation for SIM0505 by FDA
6M ago
NXTC
NextCure trading resumes
PremiumThe FlyNextCure trading resumes
7M ago
NXTC
NextCure trading halted, volatility trading pause
Premium
The Fly
NextCure trading halted, volatility trading pause
7M ago
NXTC
NextCure Updates ADC Pipeline Progress and Cash Runway
Premium
Company Announcements
NextCure Updates ADC Pipeline Progress and Cash Runway
8M ago
8K
NXTC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >